布鲁克在 Sierra SPR 平台上实现高通量多路复用 HTS

用于高通量筛选 （HTS） 的 Sierra 表面等离子体共振 （SPR） Pro 系列

创新的Sierra SPR-32 Pro允许多重HTS深入了解动力学，而不会影响样品的灵敏度和性质

通过无标记高温超导酶对分子相互作用的SPR洞察，以支持药物发现

布鲁克 Sierra SPR-32 Pro 为生物制剂和小分子候选药物的开发提供通量优化的检测装置。抗原等单一分析物可同时检测多达 31 种捕获抗体 （A）。同一平台还允许通过一次实验 （B） 针对一到三个靶标测试多达 8 种分析物。后一种设置与自动化相结合，为SPR提供了行业领先的吞吐量。 （图示：美国商业资讯）

2022 年 2 月 7 日东部标准时间上午 07：01

波士顿--（美国商业资讯）--在SLAS2022国际会议暨展览会上，布鲁克公司（纳斯达克股票代码：BRKR）宣布推出一项多重检测方法，将SPR的高通量筛选提升到一个新的水平。布鲁克 Sierra SPR-32 Pro 的创新微流体系统提供独特的 8x4 阵列，每次进样可并行读取 32 个测量传感器点，具有出色的鲁棒性。这种配置提供了高通量，同时保持了生物制剂和小分子候选药物开发的灵活性，例如，用于测试一种抗原对抗31种抗体，8种小分子针对3种靶蛋白，每个通道一个参比。

“布鲁克 SPR 系统通过我们的并行读数（独特的高灵敏度 SPR 检测系统）与最先进的自动化相结合，以最高的吞吐量和数据质量为先导开发流程提供不可或缺的信息丰富的数据。”

推特这个

布鲁克令人印象深刻地展示了Sierra SPR-32 Pro平台的多重检测能力，包括先导物开发阶段典型的选择性测定，以及针对一组碳酸酐酶（具有高度相似性的蛋白质家族）的筛选分析。这些具有挑战性的例子通常需要对每种靶蛋白进行繁琐的重复相同的测定，从而减慢药物开发过程。Sierra SPR-32 Pro 的多路复用功能可将测量时间缩短多达三倍。布鲁克的高灵敏度 SPR 检测可在分析物与目标 10 之间的高分子量差异下进行测量-3，甚至支持基于片段的药物设计。

此外，布鲁克还开发了自动化 24/7 SPR 印版操作，或通过其自动化接口将 SPR 集成到 HTS 中，该接口可与来自不同供应商的通用调度软件配合使用。布鲁克的 SPR 软件可将数据和结果无缝传输到下游分析软件，例如 Genedata Screener®。

诺华生物医学研究所（瑞士巴塞尔）、Genedata（瑞士巴塞尔）和布鲁克之间的合作在应用说明“诺华通过高通量生物物理筛选应对具有挑战性的目标”中进行了描述。在5天的总实验时间中，针对一种靶蛋白和两种疾病相关突变体对10，000多种化合物进行了表征。从布鲁克的 SPR 软件到 Genedata Screener® 的无缝数据传输将数据分析时间缩短至 2.5 小时。

巴塞尔诺华生物医学研究所蛋白质科学小组实验室负责人Christine Genick博士表示：“这是一项真正的合作努力，Genedata和布鲁克真正加强了合作，使我们能够突破SPR的极限。通过建立强大的自动化和全面的处理管道，我们能够以闪电般的速度筛选和分析我们的数据。

布鲁克生物制药无标记技术总监Meike Hamester博士总结道：“布鲁克SPR系统通过我们的并行读出（独特的高灵敏度SPR检测系统）与最先进的自动化相结合，以最高的通量和数据质量为先导物开发过程提供不可或缺的信息丰富的数据。

关于布鲁克公司（纳斯达克股票代码：BRKR）

布鲁克使科学家能够取得突破性发现并开发新的应用，从而提高人类生活质量。布鲁克的高性能科学仪器以及高价值的分析和诊断解决方案使科学家能够在分子、细胞和微观水平上探索生命和材料。通过与客户的密切合作，布鲁克在生命科学分子和细胞生物学研究、应用和制药应用、显微镜和纳米分析以及工业应用中实现创新、提高生产力和客户成功。布鲁克在临床前成像、临床表型组学研究、蛋白质组学和多组学、空间和单细胞生物学、功能结构和凝聚物生物学以及临床微生物学和分子诊断学方面提供差异化的、高价值的生命科学和诊断系统和解决方案。欲了解更多信息，请访问：www.bruker.com。

Bruker Enables High-Throughput Multiplex HTS on Sierra SPR Platform

Sierra Surface Plasmon Resonance (SPR) Pro Series for High-Throughput Screening (HTS)

• Innovative Sierra SPR-32 Pro allowing multiplex HTS for insights into kinetics with no compromise in sensitivity and nature of samples

• SPR insights into molecular interactions by label-free HTS in support of drug discovery

The Bruker Sierra SPR-32 Pro offers throughput-optimized assay set-ups for the development of both biologics and small molecule drug candidates. Single analytes like an antigen can be simultaneously tested against up to 31 capture antibodies (A). The same platform also allows to test up to 8 analytes against one to three targets with a single experiment (B). The latter set-up coupled with automation provides industry-leading throughput for SPR. (Graphic: Business Wire)

• 
  

• 
  

February 07, 2022 07:01 AM Eastern Standard Time

BOSTON--(BUSINESS WIRE)--At the SLAS2022 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) is announcing a multiplexed assay taking high-throughput screening with SPR to the next level. The innovative microfluidic system of the Bruker Sierra SPR-32 Pro provides a unique 8x4 array for parallel readout of 32 measurement sensor spots per injection at exceptional robustness. This configuration offers high throughput while maintaining flexibility for the development of both, biologics and small molecule drug candidates, e.g., for testing one antigen against 31 antibodies, to 8 small molecules against 3 target proteins with a single reference per channel.

“The Bruker SPR systems provide indispensable, information-rich data for the lead development processes at highest throughput and data quality, enabled by our parallel readout, a unique high sensitivity SPR detections system, all combined with state-of-the-art automation.”

Tweet this

Bruker impressively demonstrated the multiplexing capabilities of the Sierra SPR-32 Pro platform with a selectivity assay, typical for lead development stages, and a screening assay against a set of carbonic anhydrases, a protein family with a high degree of similarity. These challenging examples typically require tedious repetitions of the same assay for each target protein, slowing down the drug development process. The multiplexing capabilities of the Sierra SPR-32 Pro reduces measurement time by up to threefold. Bruker’s highly sensitive SPR detection enables measurements at high molecular weight differences between analyte and target of 10-3, supporting even fragment-based drug design.

Moreover, Bruker has developed automated 24/7 SPR plate-handling operation, or by its automation interface for SPR integration in HTS, which works with common scheduling software from various vendors. Bruker’s SPR software features seamless transfer of data and results to downstream analysis software, e.g., to Genedata Screener®.

A collaboration between Novartis Institute of Biomedical Research (Basel, CH), Genedata (Basel, CH) and Bruker is described in the application note ‘Tackling Challenging Targets with High-Throughput Biophysical Screening at Novartis’. With a total experimental time of 5 days, more than 10,000 compounds were characterized against one target protein and two of its disease relevant mutants. The seamless data transfer from Bruker’s SPR software to Genedata Screener® reduced data analysis to 2.5 hours.

Dr. Christine Genick, Lab Head of the Protein Sciences Group at the Novartis Institute of Biomedical Research in Basel, stated: “This was a truly collaborative effort, in which Genedata and Bruker really stepped up and enabled us to push the limits of SPR. By setting up robust automation and a comprehensive processing pipeline, we were able to screen and analyze our data with lightning speed.”

Dr. Meike Hamester, Bruker Director of BioPharma Label-free Technologies, summarized: “The Bruker SPR systems provide indispensable, information-rich data for the lead development processes at highest throughput and data quality, enabled by our parallel readout, a unique high sensitivity SPR detections system, all combined with state-of-the-art automation.”

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit: www.bruker.com.